CEO Neil McFarlane Net Acquires $1.33M in ZVRA Shares Following Option Exercise
ZVRA sits 51% above its 52-week low of $6.19.
Summary
Zevra Therapeutics' President and CEO, Neil F. McFarlane, net acquired over $1.33 million worth of common stock after exercising options and selling a portion, significantly increasing his direct holdings.
Key Events · Ownership and Investor Activity · ZVRA
-
CEO Net Acquisition
President and CEO Neil F. McFarlane net acquired $1,330,581 worth of common stock, representing a significant increase in his direct ownership.
-
Option Exercise
McFarlane exercised options for 233,334 shares on January 31, 2026, contributing to the overall increase in holdings.
-
Pre-Planned Sale
A sale of 91,000 shares totaling $853,425 was executed on February 2, 2026, under a 10b5-1 plan adopted in March 2025.
-
Equity Awards Received
McFarlane also received new awards of 125,000 Restricted Stock Units and options for 250,000 shares on January 29, 2026, as part of his compensation.
Analysis · ZVRA · Life Sciences
This Form 4 filing indicates a substantial net acquisition of Zevra Therapeutics shares by President and CEO Neil F. McFarlane. While he executed a pre-planned sale of a portion of shares, the overall activity shows a significant increase in his direct ownership through the exercise of options. This net accumulation of over $1.33 million in shares by a key executive signals strong confidence in the company's future prospects.
At the time of this filing, ZVRA was trading at $9.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $526.9M. The 52-week trading range was $6.19 to $13.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.